Marked Chart Marked Chart Closed

The Marked Chart Wire · Health

Biohaven

Biohaven shares phase 1 results for BHV-1530

Biohaven disclosed early trial data for its antibody-drug conjugate BHV-1530. The findings showed that patients with FGFR3-altered cancers experienced shrinkage of tumors and other clinical benefits.

Illustration for the Health desk

Learn the basics

New to this? Read: Reading a stock chart

More Health news

Fast headlines, summarized. Not verified and not advice. Check the full story before you act.